Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson, Ann‐Lii Cheng, Shukui Qin et al.|Journal of Clinical Oncology|2013Cited by 775
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJosep M. Llovet, Joong‐Won Park, Thomas Decaens et al.|Journal of Clinical Oncology|2013Cited by 596
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of SorafenibAndrew X. Zhu, Li‐Tzong Chen, Étienne Dorval et al.|JAMA|2014Cited by 569
Recurrence of Hepatitis B-Related Hepatocellular Carcinoma Is Associated With High Viral Load at the Time of ResectionIvan Fan‐Ngai Hung, Man‐Fung Yuen, Ronnie T.P. Poon et al.|The American Journal of Gastroenterology|2008Cited by 203
G1 checkpoint establishment in vivo during embryonic liver developmentXiao Qi Wang, Ronnie T.P. Poon|BMC Developmental Biology|2014Cited by 2